- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04645589
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Kaohsiung, Taiwan, 83301
- Novartis Investigative Site
-
Keelung City, Taiwan, 20401
- Novartis Investigative Site
-
Taichung, Taiwan, 40705
- Novartis Investigative Site
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
Taipei, Taiwan, 105
- Novartis Investigative Site
-
Tao Yuan, Taiwan, 333
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged ≥ 20 years and ≤ 75 years at screening.
- Patients with written informed consent form.
- Male or female diagnosed with SLE.
Confirmed diagnosis of LN by physician. Diagnosis of LN is defined as:
a. Kidney biopsy within 1 year, with histological diagnosis of LN (class III/IV/V)
- Laboratory evidence of active nephritis: spot UPCR>0.5, and/or proteinuria > 0.5 g/24 hours, and/or greater than 3+ by dipstick, and/or cellular casts.
- Patients with LN who received EC-MPS for the first time. The patients who switched from other treatment and treatment naive patients (did not received any treatment before) can be included in this study.
- Women of childbearing potential must use effective contraception before beginning EC MPS therapy, during therapy, and for six weeks after their last dose of EC MPS.
Exclusion Criteria:
- Previous or planned kidney transplant.
- Currently receiving continuous dialysis or GFR < 30 mL/min/1.73 m2 within 3 months prior to the start of study.
- Patients with active serious digestive system disease, including infrequent cases of gastrointestinal tract ulceration with hemorrhage or perforation.
- Patients currently with life threatening conditions including malignancies, or severe infection in recent 6 months prior to start of study
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Myfortic
Oral administration
|
There is no treatment allocation.
Patients administered Myfortic by prescription that have started before inclusion of the patient into the study will be enrolled.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety profile of Enteric-coated Mycophenolate Sodium (EC-MPS) on Lupus nephritis patients
Time Frame: 12 months
|
The primary endpoint is the safety of EC-MPS in LN patients, which will be assessed via the adverse events (AEs), serious adverse events (SAEs) and deaths.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reasons for study drug discontinuation
Time Frame: 12 months
|
To describe the reasons for study drug discontinuation, including poor response, loss to follow-up, etc.
|
12 months
|
Proportion of patients with a complete response
Time Frame: month 6, month 12
|
Patients will be reported to have a complete response if their proteinuria is < 0.5 g/24 hours; or UPCR≤ 0.5.
|
month 6, month 12
|
Proportion of patients with a partial response
Time Frame: month 6, month 12
|
Patients will be reported to have a partial response if they experience any one criteria as follows:
|
month 6, month 12
|
Proportion of patients achieving renal response in estimated glomerular filtration rate (eGFR)
Time Frame: month 6, month 12
|
The proportion of patients achieving renal response in estimated glomerular filtration rate (eGFR). (eGFR within the normal range, or no less than 85% of baseline) |
month 6, month 12
|
Proportion of patients achieving inactive urinary sediment
Time Frame: month 6, month 12
|
The proportion of patients achieving inactive urinary sediment (no cellular casts)
|
month 6, month 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Kidney Diseases
- Urologic Diseases
- Connective Tissue Diseases
- Glomerulonephritis
- Lupus Erythematosus, Systemic
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Nephritis
- Lupus Nephritis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Mycophenolic Acid
Other Study ID Numbers
- CERL080ATW12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lupus Nephritis
-
Imperial College LondonKarolinska Institutet; Ohio State University; Dutch Working Party on Systemic... and other collaboratorsTerminatedSystemic Lupus Erythematosus, Lupus NephritisUnited Kingdom
-
Sun Yat-sen UniversityCompleted
-
Peking UniversityCompleted
-
University Hospital, GrenobleInstitut de Biologie Structurale GrenobleCompletedSystemic Lupus Erythematosus NephritisFrance
-
Peking Union Medical College HospitalUnknownNephritis, LupusChina
-
Artiva Biotherapeutics, Inc.RecruitingLupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class IIIUnited States
-
Kyverna TherapeuticsRecruitingLupus Nephritis | Lupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class IIIGermany
-
Minia UniversityNot yet recruitingmfERG in Lupus NephritisEgypt
-
Kyverna TherapeuticsRecruitingLupus Nephritis | Lupus Nephritis - World Health Organization (WHO) Class III | Lupus Nephritis - WHO Class IVUnited States
-
RenJi HospitalNot yet recruitingWhether Belimumab Could Reduce 2-year Risk of New-onset Lupus Nephritis
Clinical Trials on Myfortic
-
University of California, San FranciscoWithdrawn
-
Novartis PharmaceuticalsTerminated
-
University of North Carolina, Chapel HillNovartis PharmaceuticalsCompleted
-
Medical College of WisconsinWithdrawnHigh Model for End-Stage Liver Disease (MELD) ScoreUnited States
-
Alexion Pharmaceuticals, Inc.RecruitingImmunoglobulin A Nephropathy | IgANSpain, United Kingdom, United States, Italy, Belgium, Germany, Colombia, Japan, China, France, Korea, Republic of, Thailand, Australia, Canada, Brazil, Malaysia, Poland, Taiwan, Austria, Greece, Israel, Netherlands, Argentina, Mexico, S... and more
-
Mayo ClinicRecruiting
-
TakedaNo longer available
-
Erasmus Medical CenterNovartis PharmaceuticalsTerminatedSystemic Lupus ErythematosusNetherlands
-
Asan Medical CenterSamsung Medical Center; Seoul National University HospitalCompletedKidney TransplantationKorea, Republic of